# Nebulized Ketamine for the Treatment of Major Depressive Disorder

> **NCT06752759** · PHASE3 · RECRUITING · sponsor: **Theresa Jacob, PhD, MPH** · enrollment: 40 (estimated)

## Conditions studied

- Severe Depression
- Moderate Depression
- Ketamine
- Midazolam
- Peripheral Nervous System Agents
- Central Nervous System Agents
- Neurotransmitter Agents
- Physiologic Effects of Drugs
- Sensory System Agents
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents, Non-Steroidal
- Depressive Symptom
- Hypnotics and Sedatives
- Anti-anxiety Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anesthetics Agent

## Interventions

- **DRUG:** nebulized ketamine
- **DRUG:** nebulized midazolam

## Key facts

- **NCT ID:** NCT06752759
- **Lead sponsor:** Theresa Jacob, PhD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-16
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06752759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06752759, "Nebulized Ketamine for the Treatment of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06752759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*